OssDsign
OssDsign - New clinical data strenghtens the case (ABG Sundal Collier)

2021-01-20 11:36
Updated clinical data from 1,055 cranioplasty procedures
8-11% infection risk with competing implant technologies
Important data points to promote further uptake
Impressive updated post-market surveillance data
OssDsign announced updated post-market surveillance data for its lead product – the cranial implant OssDsign Cranial PSI for 1,055 procedures (previously 670 procedures). At a median follow up time of 21 months (range, 0-70 months) 44 implants (4.2%) have been explanted, i.e. surgically removed due to complications. Only 2.1% of the implants were explanted due to infections, which is a slight improvement from the previously reported 2.4%. Furthermore, since most postoperative infections occur within 1-3 months, the majority of all patients (median follow-up time 21m) should be safe from such explantations going forward. Roughly 77% of the OssDsign Cranial implants were ordered by University hospitals with a high-level trauma unit, usually a sign of a new and groundbreaking technology being implemented. Importantly, this constantly growing data set comes from 181 different hospitals across Europe, Asia and the US, showing that the outcomes are reproducible across different hospitals and countries.

2.1% explantations due to infections is best-in-class
As illustrated below, infection risk across competing materials for cranioplasty typically ranges between 8-11%. Hence, it is one of the most common reasons for implant removal. These complications represent a significant economic burden. For example, the cost for managing a case of infection can cost ~USD 100K in the US. This cost usually needs to be covered by the hospital’s budget, as most infections occur within the first three months after surgery, a period in which the hospital does not receive reimbursement from the insurers for corrective surgery.

Important selling points for reimbursement and uptake
We believe this is an important data point in terms of improving reimbursement and clinical uptake as OssDsign co
...

  • Läs mer på Introduce

  • Läsaren av innehållet kan anta att ABG Sundal Collier har erhållit eller kommer att erhålla betalning för utförandet av finansiella företagstjänster från bolaget. Ersättningen är på förhand avtalad och är inte beroende av innehållet.

research@abgsc.com (Introduce.se)
ABG Sundal Collier - Introduce.se

OssDsign - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -